Companies › Meitheal Pharmaceuticals
1 active drug program in 4 registered trials: 2 Phase 4, 2 Phase 3; Infectious disease, Other; next expected readout Sep 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Fosfomycin (ZTI-01) UDP-N-acetylglucosamine 1-carboxyvinyltransferase inhibitor | MURAA | Phase 4 | Healthy Lactating Women; Infections, Bacterial; Gram Negative Infections; Urinary Tract Infections | Sep 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06440304 | Fosfomycin (ZTI-01) | Phase 4 | Infections, Bacterial | Infectious disease | Dec 2026 |
| NCT07063095 | Fosfomycin (ZTI-01) | Phase 3 | Gram Negative Infections | Infectious disease | Dec 2026 |
| NCT05709028 | Fosfomycin (ZTI-01) | Phase 3 | Urinary Tract Infections | Infectious disease | Aug 2027 |
| NCT07618299 | Fosfomycin (ZTI-01) | Phase 4 | Healthy Lactating Women | Other | Sep 2027 |
–
BioVersys SAS Avenue Therapeutics Freya Biosciences ApS BioAegis Therapeutics Aligos Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.